Proceedings before the USPTO’s Patent Trial and Appeal Board (PTAB) are often likened to oppositions before the EPO. However, there are many differences between the two types of proceedings and practitioners must adopt different strategies in order to succeed. Maeve O’Flynn and Josh Goldberg, Partners from Finnegan’s London and Washington DC offices, will compare the proceedings, and will address potential synergies and conflicts when proceedings are pending or anticipated in both jurisdictions.
Maeve O’Flynn, FInnegan LLP
Maeve O’Flynn is a European and UK patent attorney with more than a decade of in-house experience, having worked at some of the world’s largest multinational corporations in the oil and chemical industries. She has worked for a range of clients, from startups to multinationals, covering diverse technologies such as cosmetics, sustainable chemistry, and catalysis.
Joshua Goldberg, Finnegan LLP
Joshua Goldberg, leader of Finnegan’s PTAB trials section, focuses on inter partes review (IPR), covered business method (CBM), and post-grant review (PGR) proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), and on ensuing appeals to the U.S. Court of Appeals for the Federal Circuit.